(CDAX, Health Care)



D		Value Indicators:	EUR	Share data:		Description:	
Buy		DCF:	2.09	Bloomberg:	AAQ GR	Producer of implants and	
		SotP:	2.59	Reuters:	AAQG.DE	biomaterials to mend broken	bones
EUR 2.10		Peer Group:	2.97	ISIN:	DE0005066609		
		Market Snapshot:	EUR m	Shareholders:		Risk Profile (WRe):	2015e
		Market cap:	46.7	Freefloat	43.3 %	Beta:	1.5
Price	EUR 1.52	No. of shares (m):	30.8	Ratio Capital	13.3 %	Price / Book:	1.1 x
Upside	38.6 %	EV:	42.1	Jürgen W. Krebs	12.7 %	Equity Ratio:	77 %
		Freefloat MC:	20.2	Noes Beheer B.V.	10.9 %		
		Ø Trad. Vol. (30d):	39.27 th	Taaleritehdas	6.3 %		

Investment case intact - Q3 figures as expected

Stated Figure	es Q3/2	015:							Comment on Figures:
FY End: 31.12. in EUR m	Q3 15	Q3 15e	Q3 14	уоу	9M 15	9M 15e	9M 14	уоу	 Preliminary sales were already reported. EBITDA in line with expectations and in the middle of guidance range.
Sales	8.4	8.4	7.8	7 %	22.0	22.0	23.0	-4 %	 LOQTEQ sales decreased as several issues in emerging markets had similiant impact on sustances? order behavior LOOTEQ was supported.
EBITDA	0.3	0.2	0.8	-60 %	-0.3	-0.4	2.4	n.a.	significant impact on customers' order behavior. LOQTEQ was pursuit
Margin	3.8 %	2.1 %	10.3 %		-1.3 %	-2.0 %	10.6 %		a growth strategy which was mainly focused on emerging markets a
EBIT	-0.4	-0.5	0.2	n.a.	-2.3	-2.4	0.8	n.a.	the US. LOQTEQ remains the core growth driver at app.
Margin	-4.3 %	-6.1 %	3.1 %		-10.3 %	-11.0 %	3.4 %		
EPS	-0.01	-0.02	0.01	n.a.	-0.07	-0.08	0.03	n.a.	


A conference call will be hosted on Monday 16, at 2 p.m. CET. Dial: +49 (0) 69 5060 9538; Access code: 324 797 7597

aap faced several order delays in main Trauma markets in Q3. In the past, aap focused on a distribution strategy mainly based on emerging markets (so-called BRIC and SMIT countries). The company benefitted strongly from the rapid development and growth of these markets in the past. However, these countries are currently suffering from negative economic development as well as unfavourable currency exchange rates, which are affecting aap's distribution partners, resulting in order delays. For the moment, any change in the aforementioned macro-economic trends would seem difficult to predict and as a consequence the order situation remains uncertain. In regard to reducing dependence on these markets, the company is now planning to put greater focus on developed markets such as the DACH-region.

Despite current issues regarding the roll-out of LOQTEQ, there are no doubts about aap's equity story. Based on its competitive quality and the effectiveness of the IP-protected Trauma implant LOQTEQ, we expect the company to get back on track in the near future. Furthermore, aap plans to file for CE approval for its promising silver coating technology by the end of this year. Potential approval is expected in H2 2016. This approval would improve the USP of LOQTEQ and would also further increase barriers for the development of a comparable antibacterial silver coated Trauma implant. Therefore, the rating and price target are being kept unchanged. Current stock prices are perceived to be a buying opportunity as the most recent drop in the share price seems overdone in our view. Buy.

3.25 s. M.M.		FY End: 31.12. in EUR m	CAGR (14-17e)	2011	2012	2013	2014	2015e	2016e	2017e
· · · · · · · · · · · · · · · · · · ·	\mathcal{M}	Sales	3.0 %	29.2	36.4	40.0	31.6	29.3	31.8	34.5
2.76 -	ine J	Change Sales yoy		2.7 %	24.7 %	9.8 %	-21.0 %	-7.2 %	8.5 %	8.4 %
25 M 1 M	<mark>⊾ </mark> rw	Gross profit margin		85.3 %	78.4 %	72.7 %	68.8 %	65.0 %	71.0 %	73.0 %
225 W W	m / 1 / 1	EBITDA	12.3 %	4.1	7.1	7.4	2.3	-0.7	2.0	3.2
····	Mar.	Margin		14.1 %	19.6 %	18.4 %	7.2 %	-2.3 %	6.1 %	9.4 %
2 -	1.1.1.1	EBIT	-	1.2	3.2	-2.1	0.0	-2.8	-0.3	0.8
1.75 -	η –	Margin		4.0 %	8.8 %	-5.3 %	-0.1 %	-9.6 %	-0.9 %	2.4 %
		Net income	-	0.4	2.4	-2.2	-0.5	-2.9	-0.8	0.7
1.5	7716 09/16 11/16	EPS	-	0.01	0.08	-0.07	-0.01	-0.09	-0.03	0.02
seo impientate GDA)		DPS	-	0.00	0.00	0.00	0.00	-0.03	-0.01	0.01
— sep impenente — ODA	(normalised)	Dividend Yield		0.0 %	0.0 %	0.0 %	0.0 %	-2.0 %	-0.7 %	0.7 %
Rel. Performance vs C	DAX:	FCFPS		-0.03	0.10	-0.07	-0.26	-0.07	-0.10	-0.05
1 month:	-25.6 %	FCF / Market cap		-2.7 %	10.4 %	-7.3 %	-7.3 %	-4.7 %	-6.7 %	-3.5 %
6 months:	-27.8 %	EV / Sales		1.2 x	0.9 x	1.2 x	2.4 x	1.4 x	1.4 x	1.4 x
		EV / EBITDA		8.7 x	4.8 x	6.6 x	33.5 x	n.a.	23.3 x	14.5 x
Year to date:	-46.5 %	EV / EBIT		30.8 x	10.7 x	n.a.	n.a.	n.a.	n.a.	57.5 x
Trailing 12 months:	-49.6 %	P/E		96.9 x	12.5 x	n.a.	n.a.	n.a.	n.a.	75.8 x
		FCF Yield Potential		2.6 %	11.0 %	9.3 %	-0.4 %	-7.2 %	-1.9 %	1.2 %
Company events:		Net Debt		7.1	3.9	3.2	-7.8	-4.7	-1.2	0.1
		ROE		0.8 %	4.9 %	-4.4 %	-1.0 %	-6.7 %	-1.9 %	1.6 %
		ROCE (NOPAT)		1.4 %	5.2 %	-3.6 %	-0.3 %	-8.1 %	-3.2 %	1.5 %
		Guidance: (Suidance 201	5: Revenue E	EUR 27.5-31.	5m - EBITD	A EUR -1.5-1	m		






Company Background

- aap Implantate AG develops, produces and sells medical implants, which are primarily used in orthopaedics to mend fractures.
- With the business areas Trauma and Biomaterials, the company covers the entire value chain and sells the products worldwide with the focus on Europe, the USA as well as on the BRICS and SMIT markets.
- The products are sold by direct sale, international sales partners or OEMs (including Stryker, Zimmer, Biomet or Smith& Nephew).
- aap Implantate AG was founded in 1990 as a MBO from the Johnson & Johnson Group and is headquartered in Berlin. The company has 217 employees.

Competitive Quality

- aap Implantate AG has developed a patent protected Trauma implant (LOQTEQ), which provides significant improvements for surgeons, hospitals and clinics as well as patients.
- Additionally aap has a promising product pipeline with an antibacterial silver coating for the implants as well as resorbable magnesium implants.
- The sale of the Dutch subsidiary has provided the company with sufficient financial funds to grow organically and inorganically.
- In the Biomaterials division, aap has established a network with the largest Medtech companies (e.g. Zimmer, Stryker, Smith &Nephew, Johnson & Johnson).





DCF model

	Detaile	d forecas	t period				Т	ransition	al period					Term. Value
Figures in EUR m	2015e	2016e	2017e	2018e	2019e	2020e	2021e	2022e	2023e	2024e	2025e	2026e	2027e	
Sales	29.3	31.8	34.5	37.4	40.6	44.2	48.2	51.5	55.2	59.3	63.9	69.0	74.6	
Sales change	-7.2 %	8.5 %	8.4 %	8.4 %	8.6 %	8.8 %	9.0 %	6.9 %	7.2 %	7.4 %	7.7 %	7.9 %	8.2 %	2.5 %
EBIT	-2.8	-0.3	0.8	1.4	2.2	3.2	4.2	5.6	7.4	9.7	13.4	14.5	15.7	
EBIT-margin	-9.6 %	-0.9 %	2.4 %	3.9 %	5.5 %	7.2 %	8.8 %	10.9 %	13.4 %	16.4 %	21.0 %	21.0 %	21.0 %	
Tax rate (EBT)	-7.4 %	-347.2 %	28.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	
NOPAT	-3.0	-1.2	0.6	1.1	1.7	2.4	3.2	4.2	5.5	7.3	10.1	10.9	11.8	
Depreciation	2.1	2.2	2.4	2.4	2.6	2.9	3.1	3.3	3.6	3.9	4.2	4.5	4.8	
in % of Sales	7.3 %	7.0 %	7.0 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	
Changes in provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in Liquidity from														
- Working Capital	-1.9	1.2	1.3	0.4	1.5	1.6	1.8	1.5	-1.1	1.6	1.8	2.0	2.3	
- Capex	3.3	3.4	3.4	2.4	2.6	2.9	3.1	3.3	3.6	3.9	4.2	4.5	4.8	
Capex in % of Sales	11.3 %	10.7 %	9.9 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	-2.3	-3.6	-1.7	0.7	0.2	0.8	1.4	2.7	6.6	5.7	8.3	8.8	9.5	11
PV of FCF	-2.3	-3.3	-1.4	0.5	0.2	0.5	0.8	1.4	3.2	2.5	3.3	3.2	3.1	52
share of PVs		-10.87 %						29.00) %					81.87 %
Model parameter							Valuati	on (m)						
Derivation of WACC:			Derivation	of Beta:			Presen	t values 20)27e	1	2			
							Termin	al Value		5	2			
Debt ratio	0.00 %		Financial S	Strength		1.20	Financi	al liabilities	5		9			
Cost of debt (after tax)	4.2 %		Liquidity (s	hare)		1.50	Pensio	n liabilities			0			
Market return	7.00 %		Cyclicality			1.40	Hybrid	capital			0			
Risk free rate	1.50 %		Transpare	псу		1.80	-	y interest			0			
			Others			1.47		val. of inve	estments		0			
		-					Liquidit	у			9	No. of sha	ires (m)	30.8
WACC	9.61 %		Beta			1.48	Equity	Value		6	4	Value per	share (E	JR) 2.09

Sensitivity Value per Share (EUR)

		Terminal (Growth								Delta EBIT	-margin					
Beta	WACC	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	3.00 %	3.25 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.66	10.6 %	1.56	1.60	1.64	1.68	1.72	1.76	1.81	1.66	10.6 %	1.40	1.49	1.58	1.68	1.77	1.86	1.96
1.57	10.1 %	1.73	1.78	1.82	1.87	1.92	1.97	2.03	1.57	10.1 %	1.57	1.67	1.77	1.87	1.97	2.06	2.16
1.52	9.9 %	1.83	1.87	1.92	1.97	2.03	2.09	2.16	1.52	9.9 %	1.67	1.77	1.87	1.97	2.08	2.18	2.28
1.48	9.6 %	1.93	1.98	2.03	2.09	2.15	2.22	2.29	1.48	9.6 %	1.77	1.88	1.98	2.09	2.19	2.30	2.40
1.43	9.4 %	2.03	2.09	2.15	2.21	2.28	2.35	2.43	1.43	9.4 %	1.89	2.00	2.10	2.21	2.32	2.43	2.54
1.38	9.1 %	2.15	2.21	2.28	2.35	2.42	2.50	2.59	1.38	9.1 %	2.01	2.12	2.23	2.35	2.46	2.57	2.68
1.29	8.6 %	2.41	2.48	2.56	2.65	2.74	2.85	2.96	1.29	8.6 %	2.29	2.41	2.53	2.65	2.77	2.89	3.01

• In 2013, one-third of the revenue was generated in the Trauma division and two-thirds in the Biomaterials division.

• This ratio will turn around in the medium term. As of 2020, Trauma is expected to generate almost 65% of revenue.

• In 2015e, the Trauma division is expected to break even.

• The EBIT margin in perpetuity is assumed at 21%. With successful market penetration, higher margins are possible.

- Beta is relatively low owing to the good financial situation and the sector's resistance to cyclicality.



Valuation							
	2011	2012	2013	2014	2015e	2016e	2017e
Price / Book	0.6 x	0.6 x	1.0 x	1.9 x	1.1 x	1.2 x	1.1 x
Book value per share ex intangibles	0.34	0.37	1.06	0.99	0.84	0.79	0.81
EV / Sales	1.2 x	0.9 x	1.2 x	2.4 x	1.4 x	1.4 x	1.4 x
EV / EBITDA	8.7 x	4.8 x	6.6 x	33.5 x	n.a.	23.3 x	14.5 x
EV / EBIT	30.8 x	10.7 x	n.a.	n.a.	n.a.	n.a.	57.5 x
EV / EBIT adj.*	30.8 x	10.7 x	n.a.	n.a.	n.a.	n.a.	57.5 x
P / FCF	n.a.	9.6 x	n.a.	n.a.	n.a.	n.a.	n.a.
P/E	96.9 x	12.5 x	n.a.	n.a.	n.a.	n.a.	75.8 x
P / E adj.*	96.9 x	12.5 x	n.a.	n.a.	n.a.	n.a.	75.8 x
Dividend Yield	0.0 %	0.0 %	0.0 %	0.0 %	-2.0 %	-0.7 %	0.7 %
Free Cash Flow Yield Potential	2.6 %	11.0 %	9.3 %	-0.4 %	-7.2 %	-1.9 %	1.2 %
*Adjustments made for: -							



Consolidated profit & loss


In EUR m	2011	2012	2013	2014	2015e	2016e	2017e
Sales	29.2	36.4	40.0	31.6	29.3	31.8	34.5
Change Sales yoy	2.7 %	24.7 %	9.8 %	-21.0 %	-7.2 %	8.5 %	8.4 %
Increase / decrease in inventory	0.8	0.2	-1.0	2.1	0.0	0.0	0.0
Own work capitalised	3.0	2.7	2.0	0.3	0.9	1.0	1.7
Total Sales	33.0	39.3	41.0	34.0	30.2	32.8	36.2
Material Expenses	8.1	10.8	12.0	12.3	11.1	10.2	11.0
Gross profit	24.9	28.6	29.1	21.7	19.1	22.6	25.2
Gross profit margin	85.3 %	78.4 %	72.7 %	68.8 %	65.0 %	71.0 %	73.0 %
Personnel expenses	11.9	13.5	14.6	12.2	12.6	12.6	13.5
Other operating income	1.9	3.3	4.3	3.1	3.0	3.1	3.3
Other operating expenses	10.8	11.2	11.4	10.3	10.1	11.2	11.8
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	4.1	7.1	7.4	2.3	-0.7	2.0	3.2
Margin	14.1 %	19.6 %	18.4 %	7.2 %	-2.3 %	6.1 %	9.4 %
Depreciation of fixed assets	1.1	1.1	2.2	0.8	0.7	0.6	0.7
EBITA	3.1	6.0	5.2	1.5	-1.3	1.3	2.5
Amortisation of intangible assets	1.9	2.8	7.3	1.5	1.5	1.6	1.7
Goodwill amortization	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	1.2	3.2	-2.1	0.0	-2.8	-0.3	0.8
Margin	4.0 %	8.8 %	-5.3 %	-0.1 %	-9.6 %	-0.9 %	2.4 %
EBIT adj.	1.2	3.2	-2.1	0.0	-2.8	-0.3	0.8
Interest income	0.1	0.0	0.0	0.0	0.3	0.3	0.3
Interest expenses	0.6	0.5	0.2	0.1	0.2	0.2	0.2
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	0.6	2.7	-2.3	-0.2	-2.7	-0.2	0.9
Margin	2.1 %	7.5 %	-5.7 %	-0.6 %	-9.2 %	-0.5 %	2.7 %
Total taxes	0.2	0.3	-0.2	0.3	0.2	0.6	0.3
Net income from continuing operations	0.4	2.4	-2.0	-0.5	-2.9	-0.8	0.7
Income from discontinued operations (net of tax)	0.0	0.0	-0.1	0.0	0.0	0.0	0.0
Net income before minorities	0.4	2.4	-2.2	-0.5	-2.9	-0.8	0.7
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	0.4	2.4	-2.2	-0.5	-2.9	-0.8	0.7
Margin	1.3 %	6.6 %	-5.4 %	-1.4 %	-9.9 %	-2.4 %	1.9 %
Number of shares, average	29.6	30.7	30.7	30.7	30.8	30.8	30.8
EPS	0.01	0.08	-0.07	-0.01	-0.09	-0.03	0.02
EPS adj.	0.01	0.08	-0.07	-0.01	-0.09	-0.03	0.02
*Adjustments made for:							

Guidance: Guidance 2015: Revenue EUR 27.5-31.5m - EBITDA EUR -1.5-1m


Financial Ratios

	2011	2012	2013	2014	2015e	2016e	2017e
Total Operating Costs / Sales	98.9 %	88.5 %	84.2 %	100.4 %	105.3 %	96.9 %	95.6 %
Operating Leverage	23.1 x	7.1 x	n.a.	4.7 x	-833.4 x	-10.6 x	n.a.
EBITDA / Interest expenses	6.8 x	13.7 x	40.6 x	28.8 x	n.m.	9.8 x	16.2 x
Tax rate (EBT)	36.1 %	11.5 %	10.0 %	-162.1 %	-7.4 %	-347.2 %	28.0 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	31.8 %	39.9 %	46.8 %
Sales per Employee	109,793	137,932	336,042	213,473	n.a.	n.a.	n.a.










Performance per Share



COMMENT

1

Published 16.11.2015

5




Consolidated balance sheet

In EUR m	2011	2012	2013	2014	2015e	2016e	2017e
Assets							
Goodwill and other intangible assets	38.2	39.4	14.5	15.2	15.7	16.1	16.4
thereof other intangible assets	5.5	5.1	0.9	0.5	1.0	1.5	1.7
thereof Goodwill	12.5	12.5	1.6	1.6	1.6	1.6	1.6
Property, plant and equipment	5.1	5.1	5.9	7.7	8.3	9.1	9.8
Financial assets	0.4	0.4	1.8	1.7	1.7	1.7	1.7
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	43.7	44.9	22.2	24.5	25.7	26.9	27.9
Inventories	14.0	13.9	9.4	9.4	8.6	9.4	10.1
Accounts receivable	5.5	4.2	7.0	9.3	8.0	8.7	9.5
Liquid assets	2.2	3.7	1.6	12.2	9.0	5.6	4.2
Other short-term assets	0.8	1.8	25.0	2.4	2.4	2.4	2.4
Current assets	22.5	23.7	43.0	33.3	28.1	26.1	26.3
Total Assets	66.2	68.6	65.2	57.9	53.8	53.0	54.2
Liabilities and shareholders' equity							
Subscribed capital	30.7	30.7	30.7	30.7	30.7	30.7	30.7
Capital reserve	40.4	18.6	18.8	17.6	17.6	17.6	17.6
Retained earnings	0.2	0.2	0.7	0.7	-3.1	-4.2	-3.2
Other equity components	-23.0	1.4	-3.1	-3.6	-3.6	-3.6	-3.6
Shareholders' equity	48.4	50.9	47.0	45.4	41.6	40.5	41.5
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	48.4	50.9	47.0	45.4	41.6	40.5	41.5
Provisions	0.2	0.2	0.3	0.4	0.4	0.4	0.4
thereof provisions for pensions and similar obligations	0.0	0.0	0.0	0.1	0.1	0.1	0.1
Financial liabilites (total)	9.2	7.6	4.7	4.3	4.3	4.3	4.3
thereof short-term financial liabilities	5.5	4.5	2.6	2.0	2.0	2.0	2.0
Accounts payable	3.1	3.3	2.9	2.9	2.7	3.0	3.2
Other liabilities	5.2	6.7	10.4	4.8	4.8	4.8	4.8
Liabilities	17.8	17.7	18.2	12.4	12.2	12.5	12.7
Total liabilities and shareholders' equity	66.2	68.6	65.2	57.9	53.8	53.0	54.2

Financial Ratios

	2011	2012	2013	2014	2015e	2016e	2017e
Efficiency of Capital Employment							
Operating Assets Turnover	1.4 x	1.9 x	2.0 x	1.3 x	1.3 x	1.3 x	1.3 x
Capital Employed Turnover	0.5 x	0.7 x	0.8 x	0.8 x	0.8 x	0.8 x	0.8 x
ROA	0.9 %	5.4 %	-9.7 %	-1.9 %	-11.3 %	-2.9 %	2.4 %
Return on Capital							
ROCE (NOPAT)	1.4 %	5.2 %	-3.6 %	-0.3 %	-8.1 %	-3.2 %	1.5 %
ROE	0.8 %	4.9 %	-4.4 %	-1.0 %	-6.7 %	-1.9 %	1.6 %
Adj. ROE	0.8 %	4.9 %	-4.4 %	-1.0 %	-6.7 %	-1.9 %	1.6 %
Balance sheet quality							
Net Debt	7.1	3.9	3.2	-7.8	-4.7	-1.2	0.1
Net Financial Debt	7.1	3.9	3.1	-7.9	-4.8	-1.3	0.0
Net Gearing	14.7 %	7.7 %	6.7 %	-17.2 %	-11.2 %	-3.0 %	0.3 %
Net Fin. Debt / EBITDA	171.4 %	54.4 %	42.6 %	n.a.	n.a.	n.a.	0.2 %
Book Value / Share	1.6	1.7	1.5	1.5	1.3	1.3	1.3
Book value per share ex intangibles	0.3	0.4	1.1	1.0	0.8	0.8	0.8



Consolidated cash flow statement




In EUR m	2011	2012	2013	2014	2015e	2016e	2017€
Net income	0.4	2.4	-2.2	-0.5	-2.9	-0.8	0.7
Depreciation of fixed assets	1.1	1.1	2.2	0.8	0.7	0.6	0.7
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	1.9	2.8	7.3	1.5	1.5	1.6	1.7
Increase/decrease in long-term provisions	0.0	0.0	0.0	0.2	0.0	0.0	0.0
Other non-cash income and expenses	0.2	-1.9	0.0	-3.0	0.0	0.0	0.0
Cash Flow	3.5	4.5	7.3	-1.0	-0.8	1.5	3.1
Increase / decrease in inventory	-0.5	1.4	-4.6	-2.0	0.8	-0.8	-0.7
Increase / decrease in accounts receivable	0.0	0.0	0.0	0.0	1.3	-0.7	-0.8
Increase / decrease in accounts payable	0.2	1.3	0.8	0.0	-0.2	0.3	0.2
Increase / decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	-0.3	2.6	-3.8	-2.0	1.9	-1.2	-1.3
Net cash provided by operating activities	3.2	7.1	3.5	-2.9	1.1	0.3	1.8
Investments in intangible assets	-3.1	-2.8	-5.7	-2.0	-2.0	-2.0	-2.0
Investments in property, plant and equipment	-0.9	-1.1	-1.1	-1.2	-1.3	-1.4	-1.4
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.3	0.0	3.5	18.3	0.0	0.0	0.0
Net cash provided by investing activities	-3.7	-3.9	-2.2	13.2	-3.3	-3.4	-3.4
Change in financial liabilities	-1.1	-1.4	-1.5	-0.6	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	-0.9	-0.3	0.3
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	3.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	-0.1	-0.2	-1.0	0.0	0.0	0.0	0.0
Net cash provided by financing activities	1.8	-1.6	-2.5	-0.6	-0.9	-0.3	0.3
Change in liquid funds	1.2	1.5	-1.2	9.7	-3.1	-3.5	-1.3
Effects of exchange-rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	2.2	3.7	2.5	12.2	9.0	5.6	4.2

Financial Ratios


	2011	2012	2013	2014	2015e	2016e	2017e
Cash Flow							
FCF	-0.8	3.2	-2.2	-8.1	-2.2	-3.1	-1.6
Free Cash Flow / Sales	-2.6 %	8.7 %	-8.2 %	-19.4 %	-7.6 %	-9.9 %	-4.7 %
Free Cash Flow Potential	0.9	3.8	4.5	-0.3	-3.0	-0.9	0.6
Free Cash Flow / Net Profit	-197.2 %	132.3 %	151.5 %	1347.6 %	76.3 %	407.0 %	-246.8 %
Interest Received / Avg. Cash	3.8 %	1.0 %	0.0 %	0.0 %	2.8 %	4.1 %	6.1 %
Interest Paid / Avg. Debt	6.3 %	6.2 %	2.9 %	1.8 %	4.7 %	4.7 %	4.7 %
Management of Funds							
Investment ratio	13.6 %	10.7 %	17.1 %	10.1 %	11.3 %	10.7 %	9.9 %
Maint. Capex / Sales	10.1 %	8.2 %	7.5 %	7.4 %	7.3 %	7.0 %	7.0 %
Capex / Dep	134.6 %	99.8 %	72.0 %	137.6 %	154.2 %	152.7 %	140.8 %
Avg. Working Capital / Sales	54.4 %	41.0 %	34.3 %	46.5 %	50.6 %	45.6 %	45.7 %
Trade Debtors / Trade Creditors	176.5 %	129.7 %	246.6 %	315.3 %	296.3 %	290.0 %	296.9 %
Inventory Turnover	0.6 x	0.8 x	1.3 x	1.3 x	1.3 x	1.1 x	1.1 x
Receivables collection period (days)	69	42	64	107	100	100	101
Payables payment period (days)	141	110	87	88	88	108	106
Cash conversion cycle (Days)	595	379	252	274	270	322	320

Free Cash Flow Generation

CAPEX and Cash Flow in EUR m



Working Capital



COMMENT

Published 16.11.2015

2017e

7



LEGAL DISCLAIMER

This research report was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It contains selected information and does not purport to be complete. The report is based on publicly available information and data ("the information") believed to be accurate and complete. Warburg Research GmbH neither does examine the information to be accurate and complete, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these analyses concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this research report, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this document. Provided a research report is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This research report does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this report are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §34B (1) OF THE GERMAN SECURITIES TRADING ACT (WHPG) AND THE ORDINANCE ON THE ANALYSIS OF FINANCIAL INSTRUMENTS (FINANV)

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Potential, Peer Group Comparison or Sum of the Parts Model. The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

In accordance with § 5 (4) of the Ordinance on the Analysis of Financial Instruments (FinAnV) Warburg Research GmbH has implemented additional internal and organisational arrangements to prevent or to deal with conflicts of interest. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg Group.

All prices of financial instruments given in this financial analysis are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin.

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934.

3. Any recipient of the Report should effect transactions in the securities discussed in the Report only through J.P.P. Euro-Securities, Inc., Delaware.

4. J.P.P. Euro-Securities, Inc. does not accept or receive any compensation of any kind for the dissemination of the research reports from Warburg.

Reference in accordance with section 34b of the German Securities Trading Act (WpHG) and the Ordinance on the Analysis of Financial Instruments (FinAnV) regarding possible conflicts of interest with the analysed company:

Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the -1research, hold a share of more than 5% of the equity capital of the analysed company. Warburg Research, or an affiliated company, within the last twelve months participated in the management of a consortium -2for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the financial analysis. Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of -3the financial analysis, in a market based on the provision of buy or sell contracts Warburg Research, or an affiliated company, were in the last twelve months bound by a service agreement with the issuers, -4who are themselves or their financial instruments are, subject of the financial analysis, in connection with investment banking business for which a service or a promise of a service emanated. The company compiling the analysis or an affiliated company had reached an agreement on the compilation of the financial -5analysis with the analysed company. Companies affiliated with Warburg Research regularly trade financial instruments of the analysed company or derivatives of -6these. The company preparing the analysis as well as its affiliated companies and employees have other important interests in -7relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
aap Implantate	5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005066609.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.	
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.	
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.	
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.	

WARBURG RESEARCH GMBH - RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	115	63
Hold	56	31
Sell	7	4
Rating suspended	5	3
Total	183	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment banking services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	20	69
Hold	6	21
Sell	2	7
Rating suspended	1	3
Total	29	100

PRICE AND RATING HISTORY AAP IMPLANTATE AS OF 16.11.2015



The chart has markings if Warburg Research GmbH changed its rating in the last 12 months. Every marking represents the date and closing price on the day of the rating change.



EQUITIES

Roland Rapelius Head of Equities

RESEARCH

Henner Rüschmeier Head of Research hrueschmeier@warburg-research.com Lucas Boventer Renewables, Internet, Media **Christian Cohrs** Engineering, Logistics Felix Ellmann Software, IT Jörg Philipp Frey Retail, Consumer Goods Harald Hof Medtech **Ulrich Huwald** Health Care, Pharma Thilo Kleibauer Retail, Consumer Goods Eggert Kuls Engineering Andreas Pläsier Banks. Financial Services

INSTITUTIONAL EQUITY SALES

Holger Nass Head of Equity Sales, USA **Klaus Schilling** Dep. Head of Equity Sales, GER Tim Beckmann United Kingdom Lyubka Bogdanova United Kingdom, Australia Jens Buchmüller Scandinavia, Austria Paul Dontenwill USA Matthias Fritsch United Kingdom

SALES TRADING

Oliver Merckel Head of Sales Trading Michael Ilgenstein Sales Trading **Bastian Quast** Sales Trading

MACRO RESEARCH

Carsten Klude Macro Research Matthias Thiel Macro Research

+49 40 309537-290 lboventer@warburg-research.com +49 40 309537-175 ccohrs@warburg-research.com +49 40 309537-120 fellmann@warburg-research.com +49 40 309537-258 jfrey@warburg-research.com +49 40 309537-125 hhof@warburg-research.com +49 40 309537-255 uhuwald@warburg-research.com +49 40 309537-257 tkleibauer@warburg-research.com +49 40 309537-256 ekuls@warburg-research.com +49 40 309537-246 aplaesier@warburg-research.com

+49 40 3282-2673

+49 40 309537-270

rrapelius@mmwarburg.com

+49 40 3282-2669 hnass@mmwarburg.com +49 40 3282-2664 kschilling@mmwarburg.com +49 40 3282-2665 tbeckmann@mmwarburg.com +49 69 5050-7411 lboqdanova@mmwarburg.com +49 69 5050-7415 jbuchmueller@mmwarburg.com +49 40 3282-2666 pdontenwill@mmwarburg.com +49 40 3282-2696 mfritsch@mmwarburg.com

+49 40 3282-2634

+49 40 3282-2700

+49 40 3282-2701

+49 40 3282-2572

+49 40 3282-2401

bquast@mmwarburg.com

cklude@mmwarburg.com

mthiel@mmwarburg.com

omerckel@mmwarburg.com

milgenstein@mmwarburg.com

Malte Räther Technology, Telco, Internet Jochen Reichert Telco, Internet, Media J. Moritz Rieser Real Estate Arash Roshan Zamir Cap. Goods, Renewables Malte Schaumann Technology **Oliver Schwarz** Chemicals, Agriculture Marc-René Tonn Automobiles, Car Suppliers **Björn Voss** Steel, Car Suppliers Andreas Wolf Software, IT

Marie-Therese Grübner France, Switzerland Michael Kriszun United Kingdom Marc Niemann Germany Fabian Roggemann USA Sanjay Oberoi United Kingdom **Juliane Willenbruch** Roadshow/Marketing

Jörg Treptow Sales Trading Jan Walter Sales Trading

Dr. Christian Jasperneite

Investment Strategy

+49 40 309537-260 mrieser@warburg-research.com +49 40 309537-155 aroshanzamir@warburg-research.com +49 40 309537-170 mschaumann@warburg-research.com +49 40 309537-250 oschwarz@warburg-research.com +49 40 309537-259 mtonn@warburg-research.com +49 40 309537-254 bvoss@warburg-research.com +49 40 309537-140 awolf@warburg-research.com

+49 40 309537-185

+49 40 309537-130

mraether@warburg-research.com

jreichert@warburg-research.com

+49 40 3282-2630 maruebner@mmwarbura.com +49 40 3282-2695 mkriszun@mmwarburg.com +49 40 3282-2660 mniemann@mmwarburg.com +49 40 3282-2667 froggemann@mmwarburg.com +49 69 5050-7410 soberoi@mmwarburg.com +49 40 3282-2694 jwillenbruch@mmwarburg.com

> +49 40 3262-2658 jtreptow@mmwarburg.com +49 40 3262-2662 jwalter@mmwarburg.com

+49 40 3282-2439 cjasperneite@mmwarburg.com

Our research can be found under:						
Warburg Research	research.mmwarburg.com/en/index.html	Thomson	www.thomson.com			
Bloomberg	MMWA GO	Reuters	www.knowledge.reuters.cor			
FactSet	www.factset.com	Capital IQ	www.capitaliq.cor			
For access please co	ontact:					
Andrea Schaper Sales Assistance	+49 40 3282-2632 aschaper@mmwarburg.com	Kerstin Muthig Sales Assistance	+49 40 3282-270 kmuthig@mmwarburg.cor			